These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 29791043)

  • 1. Infection with ibrutinib in patients with chronic lymphocytic leukemia: How strong is the association?
    Ball S; Vutthikraivit W; Maiti A; Short NJ
    Eur J Haematol; 2018 Sep; 101(3):418-420. PubMed ID: 29791043
    [No Abstract]   [Full Text] [Related]  

  • 2. Bilateral cystoid macular edema in a patient with chronic lymphocytic leukemia treated with ibrutinib.
    Saenz-de-Viteri M; Cudrnak T
    Leuk Lymphoma; 2019 Mar; 60(3):842-844. PubMed ID: 30188238
    [No Abstract]   [Full Text] [Related]  

  • 3. Ibrutinib (Imbruvica) for chronic lymphocytic leukemia.
    Med Lett Drugs Ther; 2014 Apr; 56(1440):29-30. PubMed ID: 24736247
    [No Abstract]   [Full Text] [Related]  

  • 4. Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia.
    Bennett CL; Berger JR; Sartor O; Carson KR; Hrushesky WJ; Georgantopoulos P; Raisch DW; Norris LB; Armitage JO
    Br J Haematol; 2018 Jan; 180(2):301-304. PubMed ID: 27649938
    [No Abstract]   [Full Text] [Related]  

  • 5. Rapid flare of immune thrombocytopenia after stopping ibrutinib in a patient with chronic lymphocytic leukemia.
    Sato R; Jacob J; Gaballa S
    Leuk Lymphoma; 2018 Jul; 59(7):1738-1741. PubMed ID: 29081253
    [No Abstract]   [Full Text] [Related]  

  • 6. Refractory pure red cell aplasia associated with chronic lymphocytic leukemia successfully treated with ibrutinib.
    Goldschmidt N; Rund D
    Leuk Lymphoma; 2017 Feb; 58(2):498-500. PubMed ID: 27756158
    [No Abstract]   [Full Text] [Related]  

  • 7. Survival adjusting for crossover: phase 3 study of ibrutinib
    Coutre S; Tedeschi A; Robak T; Barr PM; Owen C; Bairey O; Burger J; Zhou C; Styles L; James DF; Kipps TJ
    Haematologica; 2018 Jun; 103(6):e249-e251. PubMed ID: 29170253
    [No Abstract]   [Full Text] [Related]  

  • 8. Is HBV prophylaxis required during CLL treatment with ibrutinib?
    Tedeschi A; Frustaci AM; Mazzucchelli M; Cairoli R; Montillo M
    Leuk Lymphoma; 2017 Dec; 58(12):2966-2968. PubMed ID: 28535112
    [No Abstract]   [Full Text] [Related]  

  • 9. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
    Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic lymphocytic leukemia, autoimmune hemolytic anemia and ibrutinib: a case report and review of the literature.
    Molica S; Levato L; Mirabelli R
    Leuk Lymphoma; 2016; 57(3):735-7. PubMed ID: 26337717
    [No Abstract]   [Full Text] [Related]  

  • 11. Rapid onset of hemophagocytic lymphohistiocytosis in a patient with refractory chronic lymphocytic leukemia treated with ibrutinib.
    Poole A; Girard N; Clayton F; Tantravahi SK
    Leuk Lymphoma; 2017 May; 58(5):1258-1261. PubMed ID: 27750463
    [No Abstract]   [Full Text] [Related]  

  • 12. Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib.
    Barrientos JC; Burger JA; Byrd JC; Hillmen P; Zhou C; Ninomoto J; James DF; Kipps TJ
    Leuk Lymphoma; 2019 Apr; 60(4):1000-1005. PubMed ID: 30277101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group.
    Michallet AS; Campidelli A; Lequeu H; Dilhuydy MS; Tournilhac O; Fornecker LM; Dupuis J; Cymbalista F; De Guibert S; Delmer A; Vilque JP; Ghez D; Leblond V; Subtil F; Feugier P; Ysebaert L
    Am J Hematol; 2017 Jun; 92(6):E105-E107. PubMed ID: 28295510
    [No Abstract]   [Full Text] [Related]  

  • 14. What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Ibrutinib should be standard frontline therapy.
    Woyach JA
    Clin Adv Hematol Oncol; 2016 May; 14(5):330-3. PubMed ID: 27379693
    [No Abstract]   [Full Text] [Related]  

  • 15. Ibrutinib, an Approved Tyrosine Kinase Inhibitor as a Potential Cause of Recurrent Polymorphic Ventricular Tachycardia.
    Tomcsányi J; Nényei Z; Mátrai Z; Bózsik B
    JACC Clin Electrophysiol; 2016 Dec; 2(7):847-849. PubMed ID: 29759770
    [No Abstract]   [Full Text] [Related]  

  • 16. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.
    Winqvist M; Asklid A; Andersson PO; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Hansson L; Österborg A
    Haematologica; 2016 Dec; 101(12):1573-1580. PubMed ID: 27198718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Munir T; Brown JR; O'Brien S; Barrientos JC; Barr PM; Reddy NM; Coutre S; Tam CS; Mulligan SP; Jaeger U; Kipps TJ; Moreno C; Montillo M; Burger JA; Byrd JC; Hillmen P; Dai S; Szoke A; Dean JP; Woyach JA
    Am J Hematol; 2019 Dec; 94(12):1353-1363. PubMed ID: 31512258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis.
    Baron M; Zini JM; Challan Belval T; Vignon M; Denis B; Alanio A; Malphettes M
    Leuk Lymphoma; 2017 Dec; 58(12):2981-2982. PubMed ID: 28554246
    [No Abstract]   [Full Text] [Related]  

  • 19. Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia.
    Lutz M; Schulze AB; Rebber E; Wiebe S; Zoubi T; Grauer OM; Keßler T; Kerkhoff A; Lenz G; Berdel WE
    Cancer Res Treat; 2017 Apr; 49(2):548-552. PubMed ID: 27456945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How I treat CLL patients with ibrutinib.
    Brown JR
    Blood; 2018 Jan; 131(4):379-386. PubMed ID: 29255067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.